| Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia M Sakurai, N Egashira, T Kawashiri, T Yano, H Ikesue, R Oishi PAIN® 147 (1-3), 165-174, 2009 | 217 | 2009 |
| A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction M Ishihara, H Ikesue, H Matsunaga, K Suemaru, K Kitaichi, K Suetsugu, ... The Clinical journal of pain 28 (5), 373-381, 2012 | 114 | 2012 |
| Pharmacokinetics of favipiravir in critically ill patients with COVID‐19 K Irie, A Nakagawa, H Fujita, R Tamura, M Eto, H Ikesue, N Muroi, K Tomii, ... Clinical and translational science 13 (5), 880-885, 2020 | 110 | 2020 |
| Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats Y Mihara, N Egashira, H Sada, T Kawashiri, S Ushio, T Yano, H Ikesue, ... Molecular Pain 7, 1744-8069-7-8, 2011 | 100 | 2011 |
| Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model T Kawashiri, N Egashira, H Watanabe, Y Ikegami, S Hirakawa, Y Mihara, ... European Journal of Pain 15 (4), 344-350, 2011 | 93 | 2011 |
| Mexiletine reverses oxaliplatin-induced neuropathic pain in rats N Egashira, S Hirakawa, T Kawashiri, T Yano, H Ikesue, R Oishi Journal of pharmacological sciences 112 (4), 473-476, 2010 | 70 | 2010 |
| Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy T Sendo, N Sakai, Y Itoh, H Ikesue, H Kobayashi, T Hirakawa, H Nakano, ... Cancer chemotherapy and pharmacology 56, 91-96, 2005 | 52 | 2005 |
| Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database S Hasegawa, H Ikesue, S Nakao, K Shimada, R Mukai, M Tanaka, ... Pharmacoepidemiology and drug safety 29 (10), 1279-1294, 2020 | 36 | 2020 |
| Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer H Ikesue, T Tsuji, K Hata, H Watanabe, K Mishima, M Uchida, N Egashira, ... Annals of Pharmacotherapy 48 (9), 1159-1165, 2014 | 33 | 2014 |
| Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells S Dohgu, Y Kataoka, H Ikesue, M Naito, T Tsuruo, R Oishi, Y Sawada Cellular and molecular neurobiology 20, 781-786, 2000 | 33 | 2000 |
| Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases H Ikesue, M Mouri, H Tomita, M Hirabatake, M Ikemura, N Muroi, ... Supportive Care in Cancer 29, 4763-4772, 2021 | 30 | 2021 |
| Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags H Ikesue, LC Vermeulen, R Hoke, JM Kolesar American Journal of Health-System Pharmacy 67 (3), 223-226, 2010 | 29 | 2010 |
| Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases H Ikesue, K Doi, M Morimoto, M Hirabatake, N Muroi, S Yamamoto, ... Cancer Chemotherapy and Pharmacology 87, 871-877, 2021 | 28 | 2021 |
| Association of hypnotic drug use with fall incidents in hospitalized elderly patients: a case-crossover study H Torii, M Ando, H Tomita, T Kobaru, M Tanaka, K Fujimoto, R Shimizu, ... Biological and pharmaceutical bulletin 43 (6), 925-931, 2020 | 28 | 2020 |
| Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis H Ikesue, K Doi, M Morimoto, M Hirabatake, N Muroi, S Yamamoto, ... Supportive Care in Cancer, 1-8, 2022 | 26 | 2022 |
| Population pharmacokinetics of favipiravir in patients with COVID‐19 K Irie, A Nakagawa, H Fujita, R Tamura, M Eto, H Ikesue, N Muroi, ... CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1161-1170, 2021 | 23 | 2021 |
| Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with advanced non-small cell lung cancer H Ikesue, H Watanabe, M Hirano, A Chikamori, K Suetsugu, Y Ryokai, ... Biological and Pharmaceutical Bulletin 38 (8), 1192-1198, 2015 | 23 | 2015 |
| Protection against the extravasation of anticancer drugs by standardization of the management system H Watanabe, H Ikesue, M Yoshida, N Yamamoto, S Sakamoto, T Koga, ... Hospital Pharmacy 43 (7), 571-576, 2008 | 22 | 2008 |
| Evaluating the safety and efficiency of robotic dispensing systems T Takase, N Masumoto, N Shibatani, Y Matsuoka, F Tanaka, ... Journal of Pharmaceutical Health Care and Sciences 8 (1), 24, 2022 | 21 | 2022 |
| Increased topical tacrolimus absorption in generalized leukemic erythroderma D Teshima, H Ikesue, Y Itoh, K Urabe, M Furue, R Oishi Annals of Pharmacotherapy 37 (10), 1444-1447, 2003 | 20 | 2003 |
